Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in T790M+ NSCLC With CNS Metastasis
NCT03257124Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- May 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03257124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257124.